AnaptysBio, Inc. manages royalty-focused financial collaborations tied to Jemperli with GSK and imsidolimab with Vanda. Following the completed separation of First Tracks Biotherapeutics, the company’s recurring updates center on royalty asset management, collaboration economics, contractual rights, stock repurchase activity, and governance changes.
News about ANAB also includes developments involving imsidolimab, a licensed antibody asset being developed by Vanda, and legal or contractual matters related to the Jemperli collaboration. Company announcements have additionally covered board and finance leadership appointments and the corporate transition from a biopharma operations business to a streamlined royalty management model.
AnaptysBio (ANAB) reported fiscal first-quarter collaboration revenue of $30.3 million, down from the same period a year earlier.
For the three months ended September 30, 2026, revenue compared with $76.3 million a year earlier, when $50 million in milestone revenue was recognized. Continuing-operations net income fell to $3.9 million from $56.3 million; basic earnings per share fell to $0.13 from $2.02. Cash, cash equivalents and investments declined to $153.0 million from $164.1 million at June 30.
Jemperli royalties increased 11% quarter over quarter. Jemperli received U.S. approval in October for adults with stage II and III MSI-H/dMMR locally advanced rectal cancer. Anaptys expects annualized Jemperli royalties payable to it to exceed $390 million as early as 2029, at GSK’s peak monotherapy sales guidance above $2.7 billion. Quimilza’s FDA target action date for generalized pustular psoriasis is December 12, 2026.
AnaptysBio (ANAB) announced that its executives are scheduled to participate in three upcoming investor conferences in London, New York and Miami.
CEO Daniel Faga will join UBS on November 17 and Evercore on December 2, 2026. CFO Chris Murphy will attend Piper Sandler on December 2, 2026. Fireside chats will be webcast on the company's investor website, with replays available for at least 30 days.
AnaptysBio (ANAB) announced that GSK received FDA approval for Jemperli for adults with stage II and III MSI-H/dMMR locally advanced rectal cancer. These biomarkers identify tumors with defects in DNA repair. Approval came ahead of the February 2027 review deadline.
In AZUR-1, investigator assessment found 68% (98/144) of evaluable patients maintained a clinical complete response—no detectable cancer—for 12 months without surgery. An exploratory analysis found 76% (110/144) had no evidence of cancer one year or more after treatment, including 12 whose complete response was confirmed after surgery. No recurrences were reported among responders after median follow-up exceeding two years. Independent central review found 47% (54/116) achieved the primary endpoint; those data continue to mature. Serious adverse reactions occurred in 20%, and adverse reactions led to permanent discontinuation in 3%.
Anaptys (ANAB) reported second quarter and transitional fiscal year 2026 results, highlighting higher collaboration revenue, strong Jemperli sales growth at partner GSK, and a large tax-driven profit in continuing operations.
GSK recorded Jemperli global net sales of $331 million for Q2 2026 (up 26% year over year) and $644 million for the first half of 2026 (up 34%). Collaboration revenue at Anaptys rose to $27.5 million for Q2 and $53.0 million for the first half, versus $22.3 million and $50.0 million a year earlier. A $181.5 million income tax benefit, mainly from releasing a valuation allowance on deferred tax assets, drove income from continuing operations to $177.3 million for Q2 and $176.4 million for the first half.
Cash, cash equivalents and investments were $164.1 million at June 30, 2026. The company noted positive interim AZUR-1 data for Jemperli and FDA PDUFA dates for Jemperli in neoadjuvant rectal cancer (February 2027) and Quimilza in GPP (December 12, 2026).
Anaptys (Nasdaq: ANAB) announced that chief financial officer Chris Murphy will present at the H.C. Wainwright 28th Annual Global Investment Conference on Tuesday, Sept. 15, 2026, at 3:30 p.m. ET. A live webcast and at least 30-day replay will be accessible via the investor section of Anaptys’ website.
Anaptys (Nasdaq: ANAB) reported Q1 2026 results and completed the spin-off of First Tracks Bio, becoming a royalty-focused company managing collaborations for Jemperli with GSK and imsidolimab with Vanda.
Q1 collaboration revenue was $25.6M, cash was $286.5M, and net loss was $52.9M. Jemperli royalties rose 44% to $24.7M. The company announced a $100M stock repurchase plan, a Dec. 12, 2026 PDUFA date for imsidolimab, and key leadership additions.
Anaptys (Nasdaq: ANAB) appointed Christopher M. Murphy as chief financial officer and Owen Hughes to its board of directors, effective May 11, 2026.
Murphy brings investment banking, corporate strategy and biotech CFO experience, while Hughes adds deep royalty management, corporate development and investment management expertise.
Anaptys (Nasdaq: ANAB) announced that Daniel Faga, president and CEO, will participate in a fireside chat at the H.C. Wainwright 2nd Annual Royalty Company Virtual Conference on Wednesday, May 6, 2026 at 1:30pm ET. Registration is available via the conference website.
Vanda Pharmaceuticals (ANAB) announced publication of a peer‑reviewed NEJM Evidence article reporting the pivotal phase III study of imsidolimab for Generalized Pustular Psoriasis (GPP).
The study findings are included in a Biologics License Application (BLA) for imsidolimab submitted to the U.S. FDA, with a target action date of December 12, 2026.
Summary not available.